New drug aimed at easing diabetic nerve pain hits roadblock

NCT ID NCT05838755

Terminated Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called GSK3858279 in 147 adults with chronic nerve pain from diabetes. The goal was to see if it could reduce pain better than a placebo. However, the trial was terminated early, so we have less information than planned.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK3858279
What this could lead to: If successful, this could point toward a new option for managing chronic nerve pain in people with diabetes.
What could go wrong: The trial was terminated early, so results are limited. It is still in early testing (Phase 2), and many drugs fail to show benefit at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic neuropathy neuralgia Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN

Contacts and locations

Locations

GSK Investigational Site

Anniston, Alabama, 36207, United States
GSK Investigational Site

Surprise, Arizona, 85378, United States
GSK Investigational Site

Cerritos, California, 90703, United States
GSK Investigational Site

Lomita, California, 90717, United States
GSK Investigational Site

Largo, Florida, 33777, United States
GSK Investigational Site

Miami, Florida, 33135, United States
GSK Investigational Site

Miami, Florida, 33175, United States
GSK Investigational Site

West Palm Beach, Florida, 33401, United States
GSK Investigational Site

Decatur, Georgia, 30030, United States
GSK Investigational Site

Chicago, Illinois, 60611, United States
GSK Investigational Site

Waltham, Massachusetts, 02451, United States
GSK Investigational Site

Williamsville, New York, 14221, United States
GSK Investigational Site

Huntersville, North Carolina, 28078, United States
GSK Investigational Site

Lancaster, South Carolina, 29720, United States
GSK Investigational Site

Cypress, Texas, 77429, United States
GSK Investigational Site

DeSoto, Texas, 75154, United States
GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

McAllen, Texas, 78501, United States
GSK Investigational Site

Bellevue, Washington, 98007, United States
GSK Investigational Site

New Westminster, British Columbia, V3L 3W4, Canada
GSK Investigational Site

Vancouver, British Columbia, V5Y 3W2, Canada
GSK Investigational Site

Winnipeg, Manitoba, R3C 0N2, Canada
GSK Investigational Site

Toronto, Ontario, L6S 0C6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2C4, Canada
GSK Investigational Site

Beijing, 100032, China
GSK Investigational Site

Guangzhou, 510000, China
GSK Investigational Site

Harbin, 150001, China
GSK Investigational Site

Luoyang, 471003, China
GSK Investigational Site

Shanghai, 200032, China
GSK Investigational Site

Wuhan, 430030, China
GSK Investigational Site

Yueyang, 414000, China
GSK Investigational Site

Corbeil-Essonnes, 91100, France
GSK Investigational Site

Mulhouse, 68100, France
GSK Investigational Site

Bad Homburg, 61348, Germany
GSK Investigational Site

Mainz, 55128, Germany
GSK Investigational Site

Münster, 48145, Germany
GSK Investigational Site

Wallerfing, 94574, Germany
GSK Investigational Site

Chiba, 260-0804, Japan
GSK Investigational Site

Fukuoka, 807-8556, Japan
GSK Investigational Site

Gunma, 370-3573, Japan
GSK Investigational Site

Hokkaido, 060-0061, Japan
GSK Investigational Site

Ibaraki, 300-0028, Japan
GSK Investigational Site

Kanagawa, 211-8533, Japan
GSK Investigational Site

Osaka, 565-0853, Japan
GSK Investigational Site

Tochigi, 321-0204, Japan
GSK Investigational Site

Tochigi, 321-0974, Japan
GSK Investigational Site

Tochigi, 322-8550, Japan
GSK Investigational Site

Tokyo, 103-0027, Japan
GSK Investigational Site

Tokyo, 104-0031, Japan
GSK Investigational Site

Tokyo, 143-0015, Japan
GSK Investigational Site

Tokyo, 160-0008, Japan
GSK Investigational Site

Częstochowa, 42-217, Poland
GSK Investigational Site

Gdynia, 81-338, Poland
GSK Investigational Site

Katowice, 40-081, Poland
GSK Investigational Site

Katowice, 40-282, Poland
GSK Investigational Site

Katowice, 40-648, Poland
GSK Investigational Site

Katowice, 40-749, Poland
GSK Investigational Site

Skorzewo, 60-185, Poland
GSK Investigational Site

Sochaczew, 96-500, Poland
GSK Investigational Site

Warsaw, 02-117, Poland
GSK Investigational Site

Cape Town, 7530, South Africa
GSK Investigational Site

Johannesburg, 2196, South Africa
GSK Investigational Site

KwaDukuza, 4450, South Africa
GSK Investigational Site

Pretoria, 0184, South Africa
GSK Investigational Site

Somerset West, 7130, South Africa
GSK Investigational Site

Bucheon-si, 422711, South Korea
GSK Investigational Site

Daejeon, 35233, South Korea
GSK Investigational Site

Seoul, 120-752, South Korea
GSK Investigational Site

Seoul, 136-705, South Korea
GSK Investigational Site

Seoul, 137-701, South Korea
GSK Investigational Site

Seoul, South Korea
GSK Investigational Site

A Coruña, 15006, Spain
GSK Investigational Site

Barcelona, 08023, Spain
GSK Investigational Site

Málaga, 29010, Spain
GSK Investigational Site

Palma de Mallorca, 07120, Spain
GSK Investigational Site

San SebastiAn de Los Rey, 28702, Spain
GSK Investigational Site

Torrevieja Alicante, 3186, Spain
GSK Investigational Site

Cannock, WS11 0BN, United Kingdom
GSK Investigational Site

Liverpool, L9 7AL, United Kingdom
GSK Investigational Site

Teesside, TS17 6EW, United Kingdom
GSK Investigational Site

West Yorkshire, LS10 1DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.